Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review.

ABSTRACT:

Background

Prostate cancer (PCa) has been considered an immunologically "cold tumor". Indeed, in advanced PCa, immune checkpoint inhibitors (ICIs) or anti-tumor vaccines have shown poor results in phase II and phase III trials with the exception of sipuleucel-T that showed a modest survival benefit. Radiotherapy and Targeted radioisotopes, such as ²²³Radium or ¹⁷⁷Lu-PSMA-617 monotherapy, contributed in prolonging the progression-free survival of PCa patients in second or third line. However, potential benefits of combination with immune therapies were inconstantly investigated and outcomes often were discordant.

Objective

Aim of this systematic review was to gather and analyze clinical evidence about benefits and risks of combining ionizing-radiation-ba

SUBMITTER: Rosenfeld R 

PROVIDER: S-EPMC12185560 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature